Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies
Kim SY, Nair DM, Romero M, Serna VA, Koleske AJ, Woodruff TK, Kurita T. Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death & Differentiation 2018, 26: 502-515. PMID: 29988075, PMCID: PMC6370889, DOI: 10.1038/s41418-018-0151-2.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsApoptosisFemaleHumansMiceOvaryPrimary Ovarian InsufficiencyTumor Suppressor Protein p53ConceptsDistinct apoptotic pathwaysDNA damage responseDamage-induced apoptosisTemporary repressionPhosphorylation of ATMOocyte-specific deletionActivation/phosphorylationKinase inhibitorsCDDP-induced apoptosisDamage responseMultiple kinasesMolecular basisP53 homologApoptotic pathwayNovel pathwayAbl kinase inhibitorsOvarian functionApoptosisPathwayRepressionTAp63αPhosphorylationOocytesATRImmature oocytes